scispace - formally typeset
H

Hartmut Göbel

Researcher at University of Kiel

Publications -  156
Citations -  10870

Hartmut Göbel is an academic researcher from University of Kiel. The author has contributed to research in topics: Migraine & Sumatriptan. The author has an hindex of 29, co-authored 155 publications receiving 9865 citations.

Papers
More filters
Journal ArticleDOI

The International Classification of Headache Disorders, 3rd edition (beta version)

Jes Olesen, +131 more
- 01 Jul 2013 - 
TL;DR: The International Classification of Headache Disorders, 3 edition (beta version), may be reproduced freely for scientific, educational or clinical uses by institutions, societies or individuals as mentioned in this paper. But the authors require the permission of the International Headache Society.
Journal ArticleDOI

Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine

Padhraig Gormley, +133 more
- 01 Aug 2016 - 
TL;DR: For example, the authors identified 44 independent single-nucleotide polymorphisms (SNPs) significantly associated with migraine risk (P < 5 × 10−8) that mapped to 38 distinct genomic loci, including 28 loci not previously reported and a locus that to date is the first to be identified on chromosome X.
Journal ArticleDOI

The Epidemiology of Headache in Germany: A Nationwide Survey of A Representative Sample on The Basis of The Headache Classification of The International Headache Society:

TL;DR: The findings suggest that the magnitude of the neurological disorders, migraine and tension-type headache, is seriously underestimated and thus constitutes a major contemporary health problem in Germany.
Journal ArticleDOI

Genome-wide association analysis identifies susceptibility loci for migraine without aura.

TL;DR: This study identifies the first susceptibility loci for migraine without aura, thereby expanding the knowledge of this debilitating neurological disorder.
Journal ArticleDOI

Petasites hybridus root (butterbur) is an effective preventive treatment for migraine.

TL;DR: Petasites extract 75 mg bid is more effective than placebo and is well tolerated as a preventive therapy for migraine, and Petasites 50 mg PO bid was not significantly more effective on the primary study endpoints.